Navigation Links
Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals' Lorcaserin Achieved Statistically Significant Weight Loss
Date:5/26/2011

Behavioral modification and LOrcaserin Second Study for Obesity Management) and BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus), and enrolled approximately 7,800 patients. BLOOM and BLOSSOM evaluated lorcaserin versus placebo in patients who are obese or patients who are overweight and have at least one weight-related co-morbid condition. BLOOM evaluated 3,182 patients over a two-year treatment period, and BLOSSOM evaluated 4,008 patients over a one-year treatment period. BLOOM-DM evaluated 604 obese and overweight patients with type 2 diabetes over a one-year treatment period. The trials included a standardized program of moderate diet and exercise guidance.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States subject to FDA approval of the NDA for lorcaserin.  

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication and use, safety, efficacy, tolerability, mechanism of action and potential of lorcaserin; the significance of biomarkers; the submission of a Marketing Authorization Application for regulatory approval of lorcaserin; the response to the CRL for the lo
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
3. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
4. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
5. KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain
6. Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
7. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
8. Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA
9. EntreMed ENMD-2076 Phase 2 Data to Be Presented at ASCO Annual Meeting
10. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
11. Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology, and medical device industries, with operations ... financial results for the fourth quarter and full year ... Net Revenues Increased 21.3% Year Over Year to $190.6 ... Year Over Year to $140.5 Million , Manufacturing ...
(Date:3/5/2015)... and TÜBINGEN, Germany , March ... Gates Foundation and CureVac today announced that the ... million (€46 million) in CureVac, a leading clinical-stage ... part of the agreement, the foundation will also ... prophylactic vaccines based on CureVac,s proprietary messenger RNA ...
(Date:3/5/2015)... March 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... quarter ended January 31, 2015 on Thursday, March 12 before ... the results at 11:00 AM ET. To ... to 10 minutes before the beginning of the call. If ... call will be available from Thursday, March 12, 2015 through ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
(Date:3/5/2015)... March 05, 2015 At the ... Beyond,” leaders in addiction treatment met today in Jackson, ... best clinical practices. Among the numerous respected speakers will ... will address the role that pain medications have had ... evidence-based treatment options. , "It is hard to believe ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Califia ... leader in the natural products coffee drinks category[1], today ... Products Expo West in Anaheim, Calif. Concentrated Cold ... concept, Califia Café, which democratizes the next wave of ... ingredients they need to become their own baristas. ...
(Date:3/5/2015)... 2015 Supply & Demand Chain Executive ... “Pros to Know” in the supply chain industry, and ... MEBC’s leadership team were included on this year’s list! ... this award due to their hard work, their commitment ... meeting and resolving client needs and challenges. ...
(Date:3/5/2015)... Minneapolis, Minn. (PRWEB) March 05, 2015 ... authority, invites healthcare organizations to participate in its ... includes data from executive and director-level positions, and ... , Last year’s report featured data on ... 28 independent children’s healthcare organizations and 7 subsidiary ...
(Date:3/5/2015)... Diego, CA (PRWEB) March 05, 2015 ... it is now running on 100% pollution-free electricity ... Arcadia Power. , As an Arcadia Power ... Protection Agency’s (EPA) Green Power Partnership requirements, joining ... Starbucks that also purchase clean energy. Earth Source ...
Breaking Medicine News(10 mins):Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 4Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Participation Is Now Open For INTEGRATED Healthcare Strategies 2015 Children’s Hospitals Executive Compensation Survey 2Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2
... to doctors and hospitals by people with the disease , , ... still reporting new cases of infection with the H1N1 swine ... visits to doctors and hospitals by people with the disease, ... official said Thursday. , "At the national level, we,re ...
... Health Promotion and ResearchWASHINGTON, May 21 The National ... for Osteoporosis and Related Bone Diseases held a briefing ... action plan for making bone health a national priority ... Health Promotion and Research Act." The proposed legislation would ...
... were more likely to have been victims , , THURSDAY, ... they started menstruating, the more likely black women were ... , The finding suggests childhood sexual abuse may increase ... more than 35,000 women, aged 21 to 69, taking ...
... Link Services, CaseworkersPHILADELPHIA, May 21 The Field ... the University of Pennsylvania has announced ... Change, Microsoft Corp. and Motorola to pilot the ... private entities, this groundbreaking interoperable, real-time technology system ...
... 2009 Issue Examines Experiences of Denton ... Center DALLAS, May 21 T-System, Inc., the ... departments and urgent care centers, today announced that its Emergency ... in a column entitled "ED Information Systems: A Guideline For ...
... drugs already approved as cancer treatments might also help ... discovery in flies of a gene, dubbed happyhour, that ... the insects, response to alcohol. , Animals with a ... alcohol,s sedative effects, the research shows. The researchers report ...
Cached Medicine News:Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 2Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 3Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 4Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 5Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 6Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 7Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 8Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 9Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 10Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 11Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 12Health News:Swine Flu Outbreak May Be Subsiding, CDC Says 13Health News:The National Coalition for Osteoporosis and Related Bone Diseases Briefed Congress on Action Plan for a National Vision for Bone Health 2Health News:The National Coalition for Osteoporosis and Related Bone Diseases Briefed Congress on Action Plan for a National Vision for Bone Health 3Health News:The National Coalition for Osteoporosis and Related Bone Diseases Briefed Congress on Action Plan for a National Vision for Bone Health 4Health News:The National Coalition for Osteoporosis and Related Bone Diseases Briefed Congress on Action Plan for a National Vision for Bone Health 5Health News:Childhood Sexual Abuse Might Spur Early Periods 2Health News:University of Pennsylvania, Montgomery County Partner on Integrated, Interoperable System Design for Child Welfare 2Health News:The T SystemEV(R) Featured in Journal of Emergency Nursing Paper on Successful EDIS Implementation 2Health News:The T SystemEV(R) Featured in Journal of Emergency Nursing Paper on Successful EDIS Implementation 3Health News:'Happy hour' gene discovery suggests cancer drugs might treat alcoholism 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: